Receptorium dopamini D3

Receptorium dopamini D3 cum scientiae abbreviatura DR3 est proteinum et in cerebro receptorium principale actionum substantiarum antipsychoticarum. In hominibus in chromosomate 3 (3q13.31) locati geni nomen est DRD3^[1]. Receptorium hoc enzymum adenylylo cyclasis inhibet. Nonnulla medicamenta in schizophreniam, morbum Parkinson, dependentias^[2] tractandis effectus suus per hoc receptorium dopamini perficiunt.

Ligandi receptorii dopamini D₃

ligandi effectus suus agonistae et agonistae partiales et antagonistae exercent. Agonistae saepe sunt medicamenta tractationis morbi Parkison, ut Apomorphinum, Bromocriptinum, Piribedilum, Pramipexolum, Ropinirolum, Rotigotinum. Exempla agonistarum partialium sunt Aripiprazolum et Buspironum, antagonistarum Haloperidolum et alia substantiae antipsychoticae.

Pathophysiologia

Morbus Parkinson

Apud homines in morbo Parkinson incasos cum symptomata temeraria contextus stimulatione receptorii D₃ suspicatus est^[3]. Observationes incidentiae illorum auctae post consumptionem medicamentorum agonistarum, quae receptoria D₃ stimulant, hanc praesumptionem adiuvant.

Syndroma membrorum inquietorum

Syndroma membrorum inquietorum (Anglice: Restless legs syndrome, abbrev. RLS) melius agonistis D₃ fiat, effectus sane hic saepe modo brevi tempore continuetur, itaque status "hyper-dopaminergicus" propositus est^[4].

Notae

↑ Descriptio loci geni DRD3.
↑ Galaj E, Ewing S, Ranaldi R (2018). "Dopamine D1 and D3 receptor polypharmacology as a potential treatment approach for substance use disorder". Neurosci Biobehav Rev
↑ Castro-Martínez XH, García-Ruiz PJ, Martínez-García C, Martínez-Castrillo JC, Vela L, Mata M6, Martínez-Torres I, Feliz-Feliz C, Palau F, Hoenicka J (2018). "Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants". Parkinsonism Relat Disord 49: 100-3
↑ Dinkins ML, Lallemand P, Clemens S (2017). "Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1 receptor". Sleep Med 40: 47-52

Nexus interni

[1] Descriptio loci geni DRD3.

[2] Galaj E, Ewing S, Ranaldi R (2018). "Dopamine D1 and D3 receptor polypharmacology as a potential treatment approach for substance use disorder". Neurosci Biobehav Rev

[3] Castro-Martínez XH, García-Ruiz PJ, Martínez-García C, Martínez-Castrillo JC, Vela L, Mata M6, Martínez-Torres I, Feliz-Feliz C, Palau F, Hoenicka J (2018). "Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants". Parkinsonism Relat Disord 49: 100-3

[4] Dinkins ML, Lallemand P, Clemens S (2017). "Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1 receptor". Sleep Med 40: 47-52

[1]

[2]

[3]

[4]